Entrada Therapeutics, Inc.

Phase 1 Confirmed

ENTR-601-44

Duchenne muscular dystrophy

Resolved

61days ago

Phase 1 readout · May 7, 2026

What's at stake Phase 1 trial results for ENTR-601-44 in Duchenne muscular dystrophy are due May 7, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 14h ago

“Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced positive topline data from Cohort 1 of the double‑blind, placebo‑controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE‑44‑201 clinical study.”

Add to calendar Post on X Reddit

Provenance